β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Status:	Completed
Conditions:	Arthritis
Therapuetic Areas:	Rheumatology
Healthy:	No
Age Range:	18 - Any
Updated:	4/21/2016
Start Date:	November 2011
End Date:	May 2013

An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective

This was an 18-month, multi-center, open-label, clinical extension study. Patients
completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to
be treated in this combined extension 3 study for any new gouty arthritis flare on demand
with one subcutaneous (s.c.) injection of canakinumab 150 mg.

Inclusion Criteria:

- Patients who have completed the second extension studies CACZ885H2356E2 or
CACZ885H2357E2

- Patients treated with canakinumab in the core studies or subsequent extensions

Exclusion Criteria:

- Pregnant or nursing (lactating) women

We found this trial at

sites

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Use our guide to learn which trials are right for you!

An Open-label Extension Study of CACZ885H2356E2 and CACZ885H2357E2 on the Treatment and Prevention of Gout Flares in Patients With Frequent Flares for Whom NSAIDs and/or Colchicine Are Contraindicated, Not Tolerated or Ineffective

Select your condition

Common Conditions

All Conditions